ANI acquires generic product from Teva

BAUDETTE, Minn. — ANI Pharmaceuticals acquired the approved abbreviated new drug application for flecainide acetate tablets USP in 50-mg, 100-mg and 150-mg dosage strengths. The antiarrhythmic drug was previously marketed by Teva Pharmaceuticals. The market for the drug was $39 million in 2014 according to data from IMS Health.  

"This acquisition further expands our near-term generic pipeline. We intend to re-launch the product within the next 12 months. We are excited that this transaction further extends the ANI-Teva relationship,” said Arthur Przybyl, president and CEO of ANI Pharmaceuticals.

ANI has 47 generic drug products currently in development, which address a total annual market size of $3 billion, according to IMS Health data.